Marken Expands Kit-Building Operations In Singapore
Marken's expansion is fully operational to support clinical-trial material supply.
Marken, a clinical supply-chain services provider, has expanded its kit-building operations in Singapore. The facility is fully operational and began shipping earlier this year. The kit-building unit in Singapore is supported by GMP operators and quality assurance personnel who operate the depot facility. The depot/kit facility is adjacent to Marken’s Singapore distribution hub, located near the Chiangi airport. Marken staff can receive drug product and kit materials at the depot, assemble and store kits, store drug product, and distribute clinical materials to investigator sites throughout Asia. Marken currently produces 15,000 kits per month and distributes more than 350,000 kits annually to investigator sites on a global basis.
The addition of the Singapore site is part of an ongoing global expansion plan within Marken. The company is considering developing an additional kit-building facility in either Miami or Brazil in the future. The company also has kit-building operations in Hamburg, Germany.
Source: Marken
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
